Dr. Kasi presented a rare pancreatic SARC case, highlighting distinct biology from PDAC. Precision oncology, molecular profiling, targeted therapies, and selective surgery may improve outcomes.

Dr. Ilson reviewed a rare duodenal adenocarcinoma case, emphasizing limited evidence, FOLFOX-based therapy, molecular profiling, and emerging RAS- and EGFR-targeted treatment strategies.

Dr. Fonkoua reviewed fibrolamellar carcinoma, highlighting surgery as the mainstay of treatment. Gemcitabine plus atezolizumab showed promise, while registries remain key to advancing research and care.

The panel reviewed Dr. Jonczak’s case on desmoid tumors, emphasizing active surveillance, symptom-guided care, TKIs and gamma-secretase inhibitors, with surgery reserved for select high-risk or life-threatening cases.

The panel highlighted precision therapy for rare tumors, noting oxaliplatin-based regimens, MEK inhibition for BRAF fusions, and histology- plus molecular-guided treatment for duodenal cancers.